Jeffrey J. Kirshner

7.0k total citations · 2 hit papers
89 papers, 5.0k citations indexed

About

Jeffrey J. Kirshner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jeffrey J. Kirshner has authored 89 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 19 papers in Surgery. Recurrent topics in Jeffrey J. Kirshner's work include Cancer Treatment and Pharmacology (16 papers), Cancer survivorship and care (15 papers) and Neutropenia and Cancer Infections (10 papers). Jeffrey J. Kirshner is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Cancer survivorship and care (15 papers) and Neutropenia and Cancer Infections (10 papers). Jeffrey J. Kirshner collaborates with scholars based in United States, Canada and France. Jeffrey J. Kirshner's co-authors include Gary R. Morrow, Patrick J. Flynn, Joseph A. Roscoe, Clifford A. Hudis, Jane T. Hickok, Gini F. Fleming, Richard E. Fine, Stephen B. Edge, Lawrence J. Solin and Timothy J. Whelan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Jeffrey J. Kirshner

87 papers receiving 4.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*

2001 616 citations Abram Recht, Stephen B. Edge et al. Journal of Clinical Oncology profile →
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update

2022 116 citations Sharon H. Giordano, Maria Alice Franzoi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey J. Kirshner United States	35	2.2k	1.2k	1.0k	939	700	89	5.0k
B. J. Kennedy United States	38	1.4k 0.6×	535 0.4×	992 1.0×	792 0.8×	436 0.6×	135	4.1k
Peter Schmid Germany	38	1.9k 0.9×	732 0.6×	358 0.3×	848 0.9×	189 0.3×	198	4.8k
Andrea Pace Italy	39	1.3k 0.6×	323 0.3×	479 0.5×	1.2k 1.3×	454 0.6×	170	4.7k
Clelia Madeddu Italy	44	1.4k 0.6×	518 0.4×	434 0.4×	565 0.6×	254 0.4×	158	5.4k
Giovanni Luca Gravina Italy	44	1.3k 0.6×	783 0.6×	475 0.5×	1.2k 1.2×	352 0.5×	187	5.2k
John W. Kugler United States	32	2.6k 1.2×	605 0.5×	516 0.5×	1.4k 1.5×	490 0.7×	62	4.5k
Tiina Saarto Finland	37	2.6k 1.2×	398 0.3×	460 0.4×	773 0.8×	194 0.3×	108	4.5k
Kurt Possinger Germany	35	2.2k 1.0×	579 0.5×	530 0.5×	788 0.8×	342 0.5×	101	4.4k
Alan K. Hatfield United States	25	1.2k 0.6×	217 0.2×	619 0.6×	557 0.6×	261 0.4×	55	4.4k
Shana L. Palla United States	33	1.6k 0.7×	673 0.5×	548 0.5×	698 0.7×	197 0.3×	80	4.8k

Countries citing papers authored by Jeffrey J. Kirshner

Since Specialization

Citations

This map shows the geographic impact of Jeffrey J. Kirshner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey J. Kirshner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey J. Kirshner more than expected).

Fields of papers citing papers by Jeffrey J. Kirshner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey J. Kirshner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey J. Kirshner. The network helps show where Jeffrey J. Kirshner may publish in the future.

Co-authorship network of co-authors of Jeffrey J. Kirshner

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey J. Kirshner. A scholar is included among the top collaborators of Jeffrey J. Kirshner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey J. Kirshner. Jeffrey J. Kirshner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giordano, Sharon H., Maria Alice Franzoi, Sarah Temin, et al.. (2022). Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2612–2635. 116 indexed citations breakdown →

Ramakrishna, Naren, Carey K. Anders, Nancy U. Lin, et al.. (2022). Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2636–2655. 41 indexed citations

Kirshner, Jeffrey J., et al.. (2021). Automated Electronic Health Record–Based Tool for Identification of Patients With Metastatic Disease to Facilitate Clinical Trial Patient Ascertainment. JCO Clinical Cancer Informatics. 5(5). 719–727. 11 indexed citations

Small, William, Stephanie L. Pugh, Lynne I. Wagner, et al.. (2021). Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841. International Journal of Radiation Oncology*Biology*Physics. 110(4). 962–972. 1 indexed citations

Adelson, Kerin B., et al.. (2017). The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. American Society of Clinical Oncology Educational Book. 37. 460–466. 20 indexed citations

Wagner, Lynne I., Stephanie L. Pugh, William Small, et al.. (2016). Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Cancer. 123(3). 485–493. 25 indexed citations

Recht, Abram, Elizabeth Comen, Richard E. Fine, et al.. (2016). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical Radiation Oncology. 6(6). e219–e234. 129 indexed citations

Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099. 258 indexed citations

Ramakrishna, Naren, Sarah Temin, Sarat Chandarlapaty, et al.. (2014). Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2100–2108. 134 indexed citations

10.

Peppone, Luke J., Michelle C. Janelsins, Anita R. Peoples, et al.. (2013). Effect of YOCAS yoga on insomnia and sleep medication usage among breast cancer patients receiving hormone therapy: A URCC CCOP randomized, controlled clinical trial.. Journal of Clinical Oncology. 31(15_suppl). 9531–9531. 2 indexed citations

11.

Wagner, Lynne I., Stephanie L. Pugh, William Small, et al.. (2013). Screening for depression in community-based radiation oncology settings: Results from RTOG 0841.. Journal of Clinical Oncology. 31(15_suppl). 9527–9527. 1 indexed citations

12.

Roscoe, Joseph A., et al.. (2008). Effect of a Nausea Expectancy Manipulation on Chemotherapy-Induced Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study. Journal of Pain and Symptom Management. 35(4). 381–387. 39 indexed citations

13.

Lilenbaum, Rogério, et al.. (2007). Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2—CALGB 30402. Journal of Clinical Oncology. 25(18_suppl). 7595–7595. 7 indexed citations

14.

Mustian, Karen M., Gary R. Morrow, Leslie Gillies, et al.. (2005). Prevalence of complementary and alternative medicine use in cancer patients during treatment. Supportive Care in Cancer. 13(10). 806–811. 245 indexed citations

15.

Huszar, Monica, et al.. (1996). Retroperitoneal Malignant Meningioma. The American Journal of Surgical Pathology. 20(4). 492–499. 29 indexed citations

16.

Ehrlich, Garth D., Frederick R. Davey, Jeffrey J. Kirshner, et al.. (1989). A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV‐I and HIV‐1: A clinical and molecular analysis. American Journal of Hematology. 30(3). 128–139. 51 indexed citations

17.

Preisler, Harvey D., Azra Raza, Amy Early, et al.. (1987). Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.. Journal of Clinical Oncology. 5(5). 722–730. 68 indexed citations

18.

Kirshner, Jeffrey J., Howard Ozer, Maura O’Leary, et al.. (1985). T-cell depletion of bone marrow does not inhibit in vitro hematopoiesis. Annals of Hematology. 50(4). 201–208. 3 indexed citations

19.

Kirshner, Jeffrey J., et al.. (1983). In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase.. PubMed. 11(7). 618–25. 5 indexed citations

20.

Ginsberg, Sandra J., et al.. (1981). Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.. PubMed. 65(5-6). 477–83. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact